RESUMO
Over the past decade, artificial intelligence (AI) and machine learning (ML) have become the breakthrough technology most anticipated to have a transformative effect on pharmaceutical research and development (R&D). This is partially driven by revolutionary advances in computational technology and the parallel dissipation of previous constraints to the collection/processing of large volumes of data. Meanwhile, the cost of bringing new drugs to market and to patients has become prohibitively expensive. Recognizing these headwinds, AI/ML techniques are appealing to the pharmaceutical industry due to their automated nature, predictive capabilities, and the consequent expected increase in efficiency. ML approaches have been used in drug discovery over the past 15-20 years with increasing sophistication. The most recent aspect of drug development where positive disruption from AI/ML is starting to occur, is in clinical trial design, conduct, and analysis. The COVID-19 pandemic may further accelerate utilization of AI/ML in clinical trials due to an increased reliance on digital technology in clinical trial conduct. As we move towards a world where there is a growing integration of AI/ML into R&D, it is critical to get past the related buzz-words and noise. It is equally important to recognize that the scientific method is not obsolete when making inferences about data. Doing so will help in separating hope from hype and lead to informed decision-making on the optimal use of AI/ML in drug development. This manuscript aims to demystify key concepts, present use-cases and finally offer insights and a balanced view on the optimal use of AI/ML methods in R&D.
Assuntos
Inteligência Artificial , Ensaios Clínicos como Assunto , Biologia Computacional , Desenvolvimento de Medicamentos , Aprendizado de Máquina , Pesquisa Farmacêutica , Projetos de Pesquisa , Animais , Inteligência Artificial/tendências , Biologia Computacional/tendências , Difusão de Inovações , Desenvolvimento de Medicamentos/tendências , Previsões , Humanos , Aprendizado de Máquina/tendências , Pesquisa Farmacêutica/tendências , Projetos de Pesquisa/tendênciasRESUMO
Complex generics are generic versions of drug products that generally have complex active ingredients, complex formulations, complex routes of delivery, complex dosage forms, are complex drug-device combination products, or have other characteristics that can make it complex to demonstrate bioequivalence or to develop as generics. These complex products (i.e. complex generics) are an important element of the United States (U.S.) Food and Drug Administration's (FDA's) Generic Drug User Fee Amendments (GDUFA) II Commitment Letter. The Center for Research on Complex Generics (CRCG) was formed by a grant from the FDA to address challenges associated with the development of complex generics. To understand these challenges, the CRCG conducted a "Survey of Scientific Challenges in the Development of Complex Generics". The three main areas of questioning were directed toward which (types of) complex products, which methods of analysis to support a demonstration of bioequivalence, and which educational topics the CRCG should prioritize. The survey was open to the public on a website maintained by the CRCG. Regarding complex products, the top three selections were complex injectables, formulations, and nanomaterials; drug-device combination products; and inhalation and nasal products. Regarding methods of analysis, the top three selections were locally-acting physiologically-based pharmacokinetic modeling; oral absorption models and bioequivalence; and data analytics and machine learning. Regarding educational topics, the top three selections were complex injectables, formulations, and nanomaterials; drug-device combination products; and data analytics, including quantitative methods and modeling & simulation. These survey results will help prioritize the CRCG's initial research and educational initiatives.
Assuntos
Medicamentos Genéricos , Educação em Farmácia/tendências , Pesquisa Farmacêutica/tendências , Aprovação de Drogas , Educação em Farmácia/estatística & dados numéricos , Pesquisa Farmacêutica/estatística & dados numéricos , Inquéritos e Questionários/estatística & dados numéricos , Equivalência Terapêutica , Estados Unidos , United States Food and Drug AdministrationAssuntos
Controle de Medicamentos e Entorpecentes/tendências , Alucinógenos/uso terapêutico , Legislação de Medicamentos/tendências , Pesquisa Farmacêutica , Reposicionamento de Medicamentos/métodos , Alucinógenos/metabolismo , Humanos , Transtornos Mentais/tratamento farmacológico , Transtornos Mentais/metabolismo , Neurobiologia , Dor/tratamento farmacológico , Pesquisa Farmacêutica/métodos , Pesquisa Farmacêutica/tendências , Psiquiatria/tendênciasRESUMO
OBJECTIVES: To summarise key contributions of the Pharmaceutical Education and Research with Regulatory Links (PEARRL) project (2016-2020) to the optimisation of existing and the development of new biopharmaceutics tools for evaluating the in vivo performance of oral drug products during the development of new drugs and at the regulatory level. KEY FINDINGS: Optimised biopharmaceutics tools: Based on new clinical data, the composition of biorelevant media for simulating the fed state conditions in the stomach was simplified. Strategies on how to incorporate biorelevant in vitro data of bio-enabling drug products into physiologically based pharmacokinetic (PBPK) modelling were proposed. Novel in vitro biopharmaceutics tools: Small-scale two-stage biphasic dissolution and dissolution-permeation setups were developed to facilitate understanding of the supersaturation effects and precipitation risks of orally administered drugs. A porcine fasted state simulated intestinal fluid was developed to improve predictions and interpretation of preclinical results using in vitro dissolution studies. Based on new clinical data, recommendations on the design of in vitro methodologies for evaluating the GI drug transfer process in the fed state were suggested. The optimized design of in vivo studies for investigating food effects: A food effect study protocol in the pig model was established which successfully predicted the food-dependent bioavailability of two model compounds. The effect of simulated infant fed state conditions in healthy adults on the oral absorption of model drugs was evaluated versus the fasted state and the fed state conditions, as defined by regulatory agencies for adults. Using PBPK modelling, the extrapolated fasted and infant fed conditions data appeared to be more useful to describe early drug exposure in infants, while extrapolation of data collected under fed state conditions, as defined by regulators for adults, failed to capture in vivo infant drug absorption. SUMMARY: Substantial progress has been made in developing an advanced suite of biopharmaceutics tools for streamlining drug formulation screening and supporting regulatory applications. These advances in biopharmaceutics were achieved through networking opportunities and research collaborations provided under the H2020 funded PEARRL project.
Assuntos
Desenvolvimento de Medicamentos , Interações Alimento-Droga/fisiologia , Farmacocinética , Administração Oral , Animais , Disponibilidade Biológica , Biofarmácia/métodos , Composição de Medicamentos/métodos , Desenvolvimento de Medicamentos/educação , Desenvolvimento de Medicamentos/métodos , Desenvolvimento de Medicamentos/tendências , Educação em Farmácia/tendências , Trato Gastrointestinal/fisiologia , Humanos , Colaboração Intersetorial , Modelos Biológicos , Pesquisa Farmacêutica/tendências , SuínosRESUMO
Biologics are complex pharmaceuticals that include formulated proteins, plasma products, vaccines, cell and gene therapy products, and biological tissues. These products are fragile and typically require cold chain for their delivery and storage. Delivering biologics, while maintaining the cold chain, whether standard (2°C to 8°C) or deepfreeze (as cold as -70°C), requires extensive infrastructure that is expensive to build and maintain. This poses a huge challenge to equitable healthcare delivery, especially during a global pandemic. Even when the infrastructure is in place, breaches of the cold chain are common. Such breaches may damage the product, making therapeutics and vaccines ineffective or even harmful. Rather than strengthening the cold chain through building more infrastructure and imposing more stringent guidelines, we suggest that money and effort are best spent on making the cold chain unnecessary for biologics delivery and storage. To meet this grand challenge in pharmaceutical research, we highlight areas where innovations are needed in the design, formulation and biomanufacturing of biologics, including point-of-care manufacturing and inspection. These technological innovations would rely on fundamental advances in our understanding of biomolecules and cells.
Assuntos
Produtos Biológicos/normas , COVID-19/terapia , Pesquisa Farmacêutica/normas , Refrigeração/normas , Produtos Biológicos/uso terapêutico , COVID-19/epidemiologia , Humanos , Pesquisa Farmacêutica/tendências , Refrigeração/tendências , Vacinas/normas , Vacinas/uso terapêuticoRESUMO
The quality of lead compounds is a key factor for determining the success of chemical probe and drug discovery programs. Given that high-throughput screening (HTS) continues to be a dominant lead generation paradigm, access to high-quality screening libraries is crucial for such efforts in both industry and academia. Here, we discuss the strategy implemented a decade ago to build from scratch one of the largest compound collections in academia, containing â¼575 000 carefully annotated small molecules, and a recent multidisciplinary effort designed to further enhance the collection to meet our research demands for the next decade.
Assuntos
Descoberta de Drogas , Ensaios de Triagem em Larga Escala/tendências , Bibliotecas de Moléculas Pequenas/normas , Descoberta de Drogas/métodos , Descoberta de Drogas/organização & administração , Humanos , Comunicação Interdisciplinar , Sondas Moleculares , Pesquisa Farmacêutica/tendênciasAssuntos
Pesquisa Biomédica/tendências , Doenças Cardiovasculares , Indústrias/tendências , Academias e Institutos , Doenças Cardiovasculares/tratamento farmacológico , Humanos , Pesquisa Farmacêutica/tendências , Parcerias Público-Privadas , Participação dos Interessados , Pesquisa Translacional Biomédica/tendênciasRESUMO
OBJECTIVE: With the popularization of cardiopulmonary resuscitation (CPR) technology, the success rate of restoration of spontaneous circulation (ROSC) is gradually improved, and the survival rate and neurological outcome of patients with cardiac arrest are improved. Currently, therapeutic methods for cerebral resuscitation after cardiac arrest are limited. In addition to mild hypothermia for clinical application, the majority of drugs remain in the animal experimental stage. Finding effective brain protection drugs has become a hot spot in the field of brain resuscitation research. This article will review the pharmaceutical progress of research for cerebral resuscitation after cardiac arrest, so that we can study the brain protection mechanism of these drugs better and more targeted.
Assuntos
Circulação Cerebrovascular/efeitos dos fármacos , Parada Cardíaca/tratamento farmacológico , Pesquisa Farmacêutica/tendências , Ressuscitação/métodos , HumanosRESUMO
The significance of proteomics in the pharmaceutical industry has increased since overcoming initial difficulties. This review discusses recent proteomics publications from pharmaceutical companies to identify new trends in proteomics applications to research and development. Applications of proteomics such as chemical proteomics, protein expression profiling, targeted protein quantitation, analysis of protein-protein interactions and post-translational modification are widely used by various sections of the industry. Technological advancements in proteomics will further accelerate pharmaceutical research and development.
Assuntos
Pesquisa Farmacêutica/métodos , Pesquisa Farmacêutica/tendências , Proteômica/métodos , Animais , Descoberta de Drogas/métodos , Descoberta de Drogas/tendências , Humanos , Processamento de Proteína Pós-Traducional , Proteômica/tendências , Transcriptoma/genéticaRESUMO
Nowadays, Design of Experiments (DoE) approach is a very popular methodology of planning and conducting experiments, where the effect of each tested factor on the studied responses is systematically examined and documented. The results obtained in such manner represent the design space more precisely than in the case of One-Variable-At-Time (OVAT) approach, leading to reliable and comprehensive results, while saving time and resources. Despite such a large increase of interest in this approach recently, its implementation in metabolomics research seems to be limited. Therefore, in this short overview, apart from summarizing some basic concepts of DoE, we wanted to provide a guideline for those who are about to plan metabolomics-related experiments. This overview is divided into four sections. In addition to the first section, which will introduce the history and basics of DoE, second part will provide concise description of the most popular experimental designs. Furthermore, third section will describe examples of DoE application in metabolomics and related studies. We will conclude with fourth section, providing you briefly with opportunities and trends in metabolomics research utilizing experimental design.
Assuntos
Metabolômica/métodos , Pesquisa Farmacêutica/métodos , Projetos de Pesquisa/normas , Guias como Assunto , Metabolômica/economia , Metabolômica/normas , Metabolômica/tendências , Pesquisa Farmacêutica/economia , Pesquisa Farmacêutica/normas , Pesquisa Farmacêutica/tendências , Fatores de TempoRESUMO
Objective. To analyze the inclusion of nanotechnology in the curricula of Integrated Master's in Pharmaceutical Sciences programs in Portugal. Methods. Information regarding curricula (general notice and curricular unit description, objectives and syllabus) from national institutions was collected from their official websites or requested by e-mail, and analyzed for the occurrence of nanotechnology and related terms. A nanotechnology inclusion in curriculum (NIC) index was developed and used to rank each institution. Results. All institutions with available data (eight out of nine) offered nanotechnology in their curricula. Both basic and applied nanotechnology-related education were offered to students but mostly from a theoretical perspective. The NIC index provided a standardized tool for comparing the institutions' programs and highlighted differences according to the relative importance of the presence of nanotechnology and related terms in curricula. Conclusion. Portuguese institutions offering integrated master's programs in pharmaceutical sciences are including nanotechnology in their curricula. However, its implementation across all institutions remains weak and requires further strengthening to meet the requirements of this emerging field in health care practice.
Assuntos
Educação em Farmácia/tendências , Nanotecnologia/educação , Academias e Institutos/organização & administração , Currículo/normas , Humanos , Pesquisa Farmacêutica/tendências , PortugalRESUMO
Ophthalmic drug discovery and development has enjoyed a recent renaissance, with a major shift away from reformulating old systemic drugs for ocular use to de novo discovery of drugs for specific ocular disease targets. This shift, coupled with a revolution in molecular biology and genetic sequencing, has uncovered an unprecedented number and variety of novel targets for therapeutic intervention in eye disease. With such a treasure chest of new science to pursue, it also creates a new challenge for translating the lab-based discoveries through the translational "valley of death" into full scale industry-led development of new, approved therapeutics to treat eye disease. This is in fact a daunting task, as the cost of drug development continues to increase and many of the new therapeutic targets are based on smaller, orphan diseases with very high unmet medical needs. This perspective focuses on the role of a nonprofit foundation, The Foundation Fighting Blindness, in fueling and supporting the advancement of new therapies for blinding inherited retinal degenerative diseases into approved therapeutics. The new collaborative model is changing the way breakthrough drugs are coming to market for patients, and innovative funding models are required to match the innovative science.
Assuntos
Organizações sem Fins Lucrativos , Doenças Retinianas/tratamento farmacológico , Descoberta de Drogas/tendências , Indústria Farmacêutica , Previsões , Terapia Genética , Humanos , Pesquisa Farmacêutica/tendências , Doenças Raras/tratamento farmacológico , Doenças Retinianas/genéticaRESUMO
Herein we describe, based on some bibliometric data, how the field of research on flavonoids has evolved over the last 25 years. The number of papers on flavonoids has risen in an exponential manner over these years, much faster than other fields on food constituents. This increase appears to be related to the contemporary explosion of interest in healthy foods, supplements and nutraceuticals. It was also probably triggered by large epidemiological studies on fruits and vegetables, and particularly on flavonoids, consumption and incidence of cancer, stroke and coronary heart disease. The widely distributed flavonols constitute the flavonoid subgroup upon which the greatest interest has been focused, followed by flavanols and more recently by anthocyanidins and other related polyphenols such as resveratrol. Research on isoflavones rapidly emerged in the 1990s but plateaued in the 2000s. In the 1990s flavonoids were mainly considered as the active components of medicinal plants, while from 2000 onward, they switched to be mainly regarded as bioactive food ingredients. We envision a continuation in the growth of research for the coming decade focused on clearly demonstrating the importance of flavonoids for human health.
Assuntos
Flavonoides , Saúde/tendências , Pesquisa Farmacêutica/tendências , Animais , Bebidas , Dietética/tendências , Epidemiologia/história , Flavonoides/química , Flavonoides/história , Alimentos , História do Século XIX , História do Século XX , História do Século XXI , Humanos , Pesquisa Farmacêutica/históriaRESUMO
The term comparative effectiveness research (CER) took center stage with passage of the American Recovery and Reinvestment Act (2009). The companion US$1.1 billion in funding prompted the launch of initiatives to train the scientific workforce capable of conducting and using CER. Passage of the Patient Protection and Affordable Care Act (2010) focused these initiatives on patients, coining the term 'patient-centered outcomes research' (PCOR). Educational and training initiatives were soon launched. This report describes the initiative of the Pharmaceutical Research and Manufacturers Association of America (PhRMA) Foundation. Through provision of grant funding to six academic Centers of Excellence, to spearheading and sponsoring three national conferences, the PhRMA Foundation has made significant contributions to creation of the scientific workforce that conducts and uses CER/PCOR.
Assuntos
Pesquisa Comparativa da Efetividade/tendências , Pesquisa Farmacêutica/tendências , Centros Médicos Acadêmicos , Associação , Humanos , Avaliação de Resultados da Assistência ao Paciente , Patient Protection and Affordable Care Act , Pesquisa Farmacêutica/educação , Faculdades de Medicina , Estados UnidosRESUMO
The American Society of Health-System Pharmacists residency accreditation standards require all postgraduate residency training programs to teach and evaluate a resident's ability to advance practice through project development and presentation, underscoring the importance of conducting research in today's professional climate. Although many residents express strong interest in research participation and contributing to the medical literature, many obstacles to publication have been identified. We aim to illustrate a deliberate approach to teaching this material and structuring the longitudinal experience in a way that maximizes resources to overcome these barriers. Such efforts should aid residents, advisors, and program directors in establishing curriculum which leads to successful completion and publication of pharmacy resident's research projects.
Assuntos
Educação de Pós-Graduação em Farmácia/métodos , Pesquisa Farmacêutica/educação , Pesquisa Farmacêutica/métodos , Residências em Farmácia/métodos , Aprendizagem Baseada em Problemas/métodos , Sociedades Farmacêuticas , Educação de Pós-Graduação em Farmácia/tendências , Humanos , Aprendizagem , Pesquisa Farmacêutica/tendências , Residências em Farmácia/tendências , Aprendizagem Baseada em Problemas/tendências , Sociedades Farmacêuticas/tendênciasRESUMO
The present review about the history of anticancer drug research in Hungary intends to call attention to the importance of studies on their mode of action. Several lines of evidence suggest that clinically usable oncopharmacological properties could be revealed by this way. Among the numerous compounds certain alkylating sugar alcohols and 2'-deoxyuridine derivatives were submitted to detailed investigations concerning their mode of action. Myelobromol with selective action on the myeloid elements of bone marrow has been justified for its application in chronic myeloid leukemia therapy and also in bone marrow ablation before transplantation. Mitolactol is able to cross bloodbrain barrier, consequently could control certain brain tumors. 5-etil-2'-deoxyuridine by reducing dihydropyrimidine dehydrogenase activity is able to increase 5-fluorouracil concentration in the blood, resulting in improved antitumor effect. In contrast, 5-hexil-2'-deoxyuridine, as an inhibitor of glycoconjugate pathway by reducing heparan sulfate production, has the ability to prevent metastasis. Noteworthy, the remarkable effects of vinca alkaloids, antiestrogens, and GNRH analogues were also presented in this review.